rSIV.F/HN-CFTR (Boehringer-Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial College London/University of Edinburgh/University of Oxford)

N/A

报告时间: 2025/01/26 15:39:00

基本信息

药物名称rSIV.F/HN-CFTR (Boehringer-Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial College London/University of Edinburgh/University of Oxford)

药物别称CFTR gene therapy (Sendai virus vector/F/HN-type SIV vector) (Boehringer-Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial College London/University of Edinburgh/University of Oxford)lentiviral vector-based gene therapy (Boehringer-Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial College London/University of Edinburgh/University of Oxford)

药物类型生物药

作用机制囊性纤维化跨膜传导调节因子刺激剂

靶点囊性纤维化跨膜传导调节因子

治疗领域 / 适应症囊性纤维化

全球批准适应症N/A

中国批准适应症N/A

首批国家/区域N/A

首批日期N/A

国家/区域德国英国

是否复方否

全球最高研发状态临床前

中国最高研发状态N/A

原研公司Uk Cystic Fibrosis Gene Therapy Consortium

注册分类N/A

研发信息

活跃公司Uk Cystic Fibrosis Gene Therapy Consortium 牛津大学 The University Of Edinburgh +[5]

非活跃公司N/A

活跃适应症囊性纤维化

非活跃适应症N/A

其他信息

ATC代码N/A